MCID: PRT013
MIFTS: 60

Portal Hypertension malady

Categories: Rare diseases, Gastrointestinal diseases, Cardiovascular diseases

Aliases & Classifications for Portal Hypertension

Aliases & Descriptions for Portal Hypertension:

Name: Portal Hypertension 12 50 14
Hypertension, Portal 50 29 42 69
Hypertension Portal 52

Classifications:



External Ids:

Disease Ontology 12 DOID:10762
ICD10 33 K76.6
ICD9CM 35 572.3
MeSH 42 D006975
NCIt 47 C3119
SNOMED-CT 64 155821005 34742003
UMLS 69 C0020541

Summaries for Portal Hypertension

NIH Rare Diseases : 50 portal hypertension is abnormally high blood pressure in branches of the portal vein, the large vein that brings blood from the intestine to the liver. portal hypertension itself does not cause symptoms, but complications from the condition can lead to an enlarged abdomen, abdominal discomfort, confusion, drowsiness and internal bleeding. it may be caused by a variety of conditions, but cirrhosis is the most common cause in western countries. treatment is generally directed toward the cause of the condition, although emergency treatment is sometimes needed for serious complications. last updated: 2/1/2012

MalaCards based summary : Portal Hypertension, also known as hypertension, portal, is related to budd-chiari syndrome and obstructive jaundice, and has symptoms including signs and symptoms, digestive An important gene associated with Portal Hypertension is SST (Somatostatin), and among its related pathways/superpathways are Signaling by GPCR and TGF-Beta Pathway. The drugs Simvastatin and Carvedilol have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and endothelial, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia : 71 Portal hypertension is hypertension (high blood pressure) in the hepatic portal system, which are the... more...

Related Diseases for Portal Hypertension

Diseases in the Portal Hypertension family:

Portal Hypertension Due to Infrahepatic Block

Diseases related to Portal Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 322)
id Related Disease Score Top Affiliating Genes
1 budd-chiari syndrome 31.5 AGTR1 F2 NOS3 VWF
2 obstructive jaundice 29.6 ALB EDN1 F2 TNF VEGFA
3 borderline leprosy 29.5 ALB GPT SST
4 sialadenitis 29.5 AGTR1 EDN1 VWF
5 pericarditis 29.2 ALB EDN1 NOS3 VEGFA VWF
6 myeloproliferative neoplasm 29.1 F2 JAK2 THPO VWF
7 membranoproliferative glomerulonephritis 28.6 ALB F2 JAK2 THPO TNF VWF
8 nodular regenerative hyperplasia 12.0
9 portal hypertension due to infrahepatic block 12.0
10 hepatoportal sclerosis 11.5
11 hypersplenism 11.4
12 splenomegaly 11.4
13 congenital hepatic fibrosis 11.3
14 banti's syndrome 11.3
15 caroli disease 11.3
16 portal vein thrombosis 11.2
17 cerebroretinal microangiopathy with calcifications and cysts 11.0
18 cholangitis, primary sclerosing 11.0
19 polycystic kidney and hepatic disease 10.9
20 littoral cell angioma of the spleen 10.9
21 myelofibrosis with myeloid metaplasia, somatic 10.9
22 cholestasis, progressive familial intrahepatic 3 10.9
23 adams-oliver syndrome 5 10.9
24 cholestasis, progressive familial intrahepatic 2 10.9
25 adams-oliver syndrome 6 10.9
26 cerebroretinal microangiopathy with calcifications and cysts 2 10.9
27 cirrhosis, north american indian childhood type 10.9
28 adams-oliver syndrome 1 10.9
29 coach syndrome 10.9
30 hepatitis 10.5
31 liver cirrhosis 10.4
32 nondystrophic myotonia 10.3 ALB F2
33 congenital dyserythropoietic anemia 10.3 ALB TNF
34 proliferating trichilemmal cyst 10.3 EDN1 NOS3
35 myopia 10.3 ALB EDN1 F2
36 thrombosis 10.3
37 liver disease 10.2
38 petrositis 10.2 AGTR1 ALB EDN1
39 alcoholic gastritis 10.2 ALB F2 SST
40 aplasia cutis congenita recessive 10.2 AGTR1 EDN1 NOS3
41 infiltrating ureter transitional cell carcinoma 10.2 ALB F2 TNF
42 lymphadenitis 10.2 AGTR1 EDN1 NOS3
43 joint disorders 10.2 AGTR1 NOS3 TNF
44 female infertility of uterine origin 10.2 ALB F2 GPT
45 bile duct cystadenocarcinoma 10.2 ALB F2 GPT
46 pyriform sinus cancer 10.2 NOS3 SST VEGFA
47 kohler's disease 10.2 ALB F2 GPT
48 depressed scar 10.2 ALB F2 TNF
49 retinal arterial macroaneurysm with supravalvular pulmonic stenosis 10.2 ALB F2 GPT
50 acute monocytic leukemia 10.2 ALB F2 GPT

Comorbidity relations with Portal Hypertension via Phenotypic Disease Network (PDN): (show all 22)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alcoholic Hepatitis Alcoholic Liver Cirrhosis
Chronic Congestive Splenomegaly Chronic Kidney Failure
Deficiency Anemia Esophageal Varix
Heart Disease Hepatic Encephalopathy
Hepatitis Hepatocellular Carcinoma
Hepatorenal Syndrome Hypersplenism
Iron Deficiency Anemia Neutropenia
Portal Vein Thrombosis Primary Biliary Cirrhosis
Protein-Energy Malnutrition Urea Cycle Disorder

Graphical network of the top 20 diseases related to Portal Hypertension:



Diseases related to Portal Hypertension

Symptoms & Phenotypes for Portal Hypertension

UMLS symptoms related to Portal Hypertension:


signs and symptoms, digestive

MGI Mouse Phenotypes related to Portal Hypertension:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 AGTR1 ALB BMPR2 EDN1 EDNRA F2
2 cardiovascular system MP:0005385 10.31 AGTR1 BMPR2 EDN1 EDNRA F2 NOS3
3 hematopoietic system MP:0005397 10.31 THPO TNF VEGFA VWF AGTR1 BMPR2
4 digestive/alimentary MP:0005381 10.29 SST TGFB1 TNF VEGFA VWF ALB
5 growth/size/body region MP:0005378 10.29 JAK2 NOS3 PKHD1 SST TGFB1 TNF
6 immune system MP:0005387 10.27 AGTR1 BMPR2 EDNRA F2 JAK2 NOS3
7 cellular MP:0005384 10.26 ALB BMPR2 EDNRA JAK2 NOS3 PKHD1
8 mortality/aging MP:0010768 10.25 PKHD1 SST TGFB1 TNF VEGFA VWF
9 endocrine/exocrine gland MP:0005379 10.18 ALB EDN1 EDNRA JAK2 NOS3 PKHD1
10 embryo MP:0005380 10.14 TGFB1 TNF VEGFA JAK2 BMPR2 EDN1
11 nervous system MP:0003631 10.1 BMPR2 EDN1 EDNRA F2 NOS3 PKHD1
12 liver/biliary system MP:0005370 10.03 ALB JAK2 NOS3 PKHD1 TGFB1 TNF
13 muscle MP:0005369 9.97 ALB BMPR2 EDN1 EDNRA NOS3 TGFB1
14 normal MP:0002873 9.96 ALB BMPR2 EDN1 EDNRA F2 JAK2
15 renal/urinary system MP:0005367 9.81 EDNRA NOS3 PKHD1 TGFB1 VEGFA AGTR1
16 respiratory system MP:0005388 9.56 BMPR2 EDNRA F2 NOS3 PKHD1 TGFB1
17 skeleton MP:0005390 9.32 BMPR2 EDN1 EDNRA F2 JAK2 NOS3

Drugs & Therapeutics for Portal Hypertension

Drugs for Portal Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 341)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
2
Carvedilol Approved, Investigational Phase 4,Phase 3 72956-09-3 2585
3
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147
4
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 3 525-66-6 4946
5
Isosorbide Dinitrate Approved Phase 4 87-33-2 6883
6
Nitric Oxide Approved Phase 4,Phase 3,Phase 2 10102-43-9 145068
7
Prazosin Approved Phase 4 19216-56-9 4893
8
Spironolactone Approved Phase 4,Phase 2,Phase 3 1952-01-7, 52-01-7 5833
9
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
10
Peginterferon alfa-2b Approved Phase 4,Phase 3 99210-65-8, 215647-85-1
11
Amlodipine Approved Phase 4 88150-42-9 2162
12
Losartan Approved Phase 4,Phase 2 114798-26-4 3961
13
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 1 58-93-5 3639
14
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
15
Terlipressin Approved, Investigational Phase 4,Phase 3,Phase 2 14636-12-5 72081
16
Octreotide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 83150-76-9 383414 6400441
17
Ethiodized oil Approved Phase 4,Phase 3 8008-53-5
18
Somatostatin Approved Phase 4,Phase 3,Phase 1,Phase 2 38916-34-6, 51110-01-1 53481605
19
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
20
Rifaximin Approved, Investigational Phase 4,Phase 2,Phase 3 80621-81-4 6436173
21
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
22
Furosemide Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 54-31-9 3440
23
Ethanolamine Oleate Approved Phase 4,Phase 3 2272-11-9 5282489
24
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
25
Metformin Approved Phase 4 657-24-9 14219 4091
26
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
27
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
28
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
29
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
30
Benzocaine Approved Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
31
Everolimus Approved Phase 4 159351-69-6 6442177
32
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
33
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
34
Mycophenolic acid Approved Phase 4 24280-93-1 446541
35
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
36
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
37
Lactulose Approved Phase 4,Phase 2 4618-18-2 11333
38
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
39
Dalteparin Approved Phase 4,Phase 3 9041-08-1
40
Dipyridamole Approved Phase 4 58-32-2 3108
41
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 772 46507594
42 Nadroparin Approved Phase 4 9041-08-1
43
Warfarin Approved Phase 4,Phase 3 81-81-2 6691 54678486
44
Azathioprine Approved Phase 4 446-86-6 2265
45
Macitentan Approved Phase 4 441798-33-0
46
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
47
Tranexamic Acid Approved Phase 4 1197-18-8 5526
48
Glucosamine Approved, Nutraceutical Phase 4 3416-24-8 439213
49
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
50 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 363)
id Name Status NCT ID Phase
1 Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis Unknown status NCT01282398 Phase 4
2 Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension Unknown status NCT01282385 Phase 4
3 Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal Unknown status NCT01059396 Phase 4
4 RCT of Carvedilol Versus Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage Unknown status NCT01070641 Phase 4
5 Transfusion Requirements in Gastrointestinal (GI) Bleeding Unknown status NCT00414713 Phase 4
6 Treatment for Prevention of Variceal Rebleeding Guided by the Hemodynamic Response Unknown status NCT00563602 Phase 4
7 Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis Unknown status NCT00332904 Phase 4
8 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4
9 Study of Long-Term Peg Intron Vs. Colchicine in Non-Responders. Unknown status NCT00179413 Phase 4
10 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4
11 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4
12 Primary Prevention of Gastric Variceal Bleeding : Endoscopic Treatment Versus Non-selective Beta-blocker Unknown status NCT01298271 Phase 4
13 Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis Unknown status NCT00669435 Phase 4
14 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4
15 Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease Unknown status NCT00144937 Phase 4
16 A Clinical Trial of the Vessel Sealing System (LigaSure) in Azygoportal Disconnection and Splenectomy in Patients With Portal Hypertension Completed NCT00965744 Phase 4
17 Effect of Taurine on Portal Hemodynamics in Patients With Advanced Liver Cirrhosis Completed NCT02344719 Phase 4
18 Secondary Prophylaxis After Variceal Bleeding in Non-Responders Completed NCT00450164 Phase 4
19 Short Course Terlipressin for Control of Acute Variceal Bleeding Completed NCT00369694 Phase 4
20 Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis Completed NCT00570622 Phase 4
21 The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed Completed NCT00534677 Phase 4
22 Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis Completed NCT01288794 Phase 4
23 Clinical Trial on the Effects of Long Term Administration of 20% Albumin in the Cardiovascular and Renal Function, And Hepatic Hemodynamics in Advanced Patients With Cirrhosis and Ascites. Completed NCT00968695 Phase 4
24 A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices Completed NCT00799851 Phase 4
25 Hemodynamic Effects of Terlipressin and High Dose Octreotide Completed NCT02119884 Phase 4
26 Time Interval for Endoscopic Variceal Ligation Completed NCT01291277 Phase 4
27 EVL (Endoscopic Variceal Ligation) Plus Vasoconstrictor vs.Ligation Plus PPI( Proton Pump Inhibitor) in the Control of Acute Esophageal Variceal Bleeding Completed NCT01112852 Phase 4
28 Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis for Variceal Bleeding Completed NCT00838864 Phase 4
29 PROPRANOLOL PLUS LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES? Completed NCT01893541 Phase 4
30 The Effect of DASH Diet on the Cardiometabolic Risks and Hepatic Function Among Type 2 Diabetic Patients Completed NCT01049321 Phase 4
31 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus Completed NCT01322308 Phase 4
32 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4
33 An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4
34 Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension Recruiting NCT02489045 Phase 4
35 Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS Recruiting NCT02925975 Phase 4
36 Evaluation Of The Portal Pressure By Doppler Ultrasound In Cirrhotic Patients Before And After Simvastatin Recruiting NCT02994485 Phase 4
37 Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection Recruiting NCT02247414 Phase 4
38 PPI and Esophagogastric Variceal Bleeding in Cirrhotic Patients (PPI: Proton Pump Inhibitors) Recruiting NCT03175731 Phase 4
39 Preventing Recurrent Bleeding After Eradication of Esophageal Varices Recruiting NCT02740166 Phase 4
40 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Recruiting NCT02344823 Phase 4
41 Carvedilol as an Adjunct to Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding Recruiting NCT02504723 Phase 4
42 The Effect of Carvedilol VS Endoscopic Therapy in Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding Recruiting NCT02695732 Phase 4
43 The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding Recruiting NCT02385422 Phase 4
44 Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Recruiting NCT02238444 Phase 4
45 Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer Recruiting NCT02081755 Phase 4
46 PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial Recruiting NCT02382016 Phase 4
47 Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Traditional Chinese Medicine and Entecavir Not yet recruiting NCT02945982 Phase 4
48 Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir Not yet recruiting NCT02945956 Phase 4
49 Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis Not yet recruiting NCT02907749 Phase 4
50 Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding Not yet recruiting NCT03023189 Phase 4

Search NIH Clinical Center for Portal Hypertension

Cochrane evidence based reviews: hypertension, portal

Genetic Tests for Portal Hypertension

Genetic tests related to Portal Hypertension:

id Genetic test Affiliating Genes
1 Portal Hypertension 29

Anatomical Context for Portal Hypertension

MalaCards organs/tissues related to Portal Hypertension:

39
Liver, Spleen, Endothelial, Pancreas, Colon, Brain, Kidney

Publications for Portal Hypertension

Articles related to Portal Hypertension:

(show top 50) (show all 1000)
id Title Authors Year
1
Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy. ( 27990835 )
2017
2
Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. ( 27910154 )
2017
3
Polycystic Liver Disease and Sarcoidosis: Unusual Coexisting Etiologies of Portal Hypertension. ( 28280650 )
2017
4
Noninvasive assessment of portal hypertension and detection of esophageal varices in cirrhosis: state-of-the-art. ( 28079668 )
2017
5
Spectrum of small-bowel mucosal abnormalities identified by capsule endoscopy in patients with portal hypertension of varied etiology. ( 28066855 )
2017
6
Outcomes of surgical shunts and transjugular intrahepatic portasystemic stent shunts for complicated portal hypertension. ( 28079252 )
2017
7
Ruxolitinib for the Treatment of Portal Hypertension in a Patient With Primary Myelofibrosis. ( 28478151 )
2017
8
Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction. ( 27896916 )
2017
9
Laparoscopic Treatment of Presinusoidal Schistosomal Portal Hypertension Associated With Postoperative Endoscopic Treatment: Results of a New Approach. ( 27661203 )
2016
10
Plasma ADAMTS-13 protein is not associated with portal hypertension or hemodynamic changes in patients with cirrhosis. ( 26775093 )
2016
11
Vanishing Bile Ducts, Cholesatatic Jaundice and Portal Hypertension Secondary to Hepatic ALECT-2 Amyloid Deposition. ( 27661974 )
2016
12
A case of idiopathic portal hypertension associated with nodular regenerative hyperplasia-like nodule of the liver and mixed connective tissue disease. ( 27151480 )
2016
13
Prenatal ultrasound and Doppler findings of progressing portal hypertension in a fetus with congenital cystic hepatobiliary disease. ( 26138679 )
2016
14
Emerging therapies for portal hypertension in cirrhosis. ( 27148904 )
2016
15
Minocycline attenuates cirrhotic cardiomyopathy and portal hypertension in a rat model: Possible involvement of nitric oxide pathway. ( 27917279 )
2016
16
Current Management of the Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis. ( 27170392 )
2016
17
Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. ( 27500382 )
2016
18
Portal hypertension: an uncommon clinical manifestation of Takayasu arteritis in a 9-year-old child. ( 27895519 )
2016
19
Effects of phased joint intervention on Rho/ROCK expression levels in patients with portal hypertension. ( 27602079 )
2016
20
Role of estrogen receptor I^ selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis. ( 27182159 )
2016
21
Very Early Presentation of Extrahepatic Portal Vein Obstruction Causing Portal Hypertension in an Infant: Uncertainties in the Management and Therapeutic Limitations. ( 27504083 )
2016
22
Effects of asymmetric dimethylarginine on renal arteries in portal hypertension and cirrhosis. ( 28082806 )
2016
23
Outcomes of partial splenic embolization in patients with massive splenomegaly due to idiopathic portal hypertension. ( 27920483 )
2016
24
Sequential shear-wave elastography of liver and spleen rules out clinically significant portal hypertension in compensated advanced chronic liver disease. ( 27196577 )
2016
25
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. ( 27993716 )
2016
26
Portal hypertension in children: High-risk varices, primary prophylaxis and consequences of bleeding. ( 27663417 )
2016
27
Liver Capsule: Portal Hypertension and Varices: Pathogenesis, Stages and Management. ( 28032650 )
2016
28
Pancreatic Adenocarcinoma Complicated by Sinistral Portal Hypertension. ( 27555987 )
2016
29
Shear-wave elastography of the liver and spleen identifies clinically significant portal hypertension: A prospective multicentre study. ( 27569696 )
2016
30
Amyloidosis: an unusual cause of portal hypertension. ( 27547738 )
2016
31
Idiopathic myelofibrosis with disseminated hepatosplenic, mesenteric, renal and pulmonary extramedullary haematopoeisis, portal hypertension and tuberculosis: initial presentation and 2a88years follow-up. ( 28011890 )
2016
32
Restructuring of the vascular bed in response to hemodynamic disturbances in portal hypertension. ( 28083082 )
2016
33
Noncirrhotic Portal Hypertension in Perinatally HIV-Infected Adolescents Treated with Didanosine-Containing Antiretroviral Regimens in Childhood. ( 27167116 )
2016
34
Pharyngeal Varices Secondary to Sinistral Portal Hypertension. ( 27144185 )
2016
35
Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension. ( 27589391 )
2016
36
A New Procedure for the Treatment of Extrahepatic Portal Hypertension in Children: Portal Cavernoma-Rex Shunt with Interposition of Grafted Portal Vessel. ( 27118711 )
2016
37
Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension. ( 26874653 )
2016
38
Rapamycin Attenuates Splenomegaly in both Intrahepatic and Prehepatic Portal Hypertensive Rats by Blocking mTOR Signaling Pathway. ( 26734934 )
2016
39
Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The sportdiet study. ( 27997989 )
2016
40
Utility of per-oral cholangioscopy in the diagnosis of portal hypertension associated biliopathy. ( 27163346 )
2016
41
Portosystemic Shunt Surgery in Patients with Idiopathic Noncirrhotic Portal Hypertension. ( 27194018 )
2016
42
Laparoscopic versus open splenectomy and devascularization for massive splenomegaly due to portal hypertension. ( 27924505 )
2016
43
A case of portal hypertension by presumed as plexiform neurofibroma at the hepatic hilum. ( 27209645 )
2016
44
Invasive group B streptococcal infection in a patient with post splenectomy for hypersplenism secondary to liver cirrhosis and portal hypertension. ( 27006743 )
2016
45
Editorial: Non-invasive estimation of HVPG by combined structural and hemodynamic evaluation of portal hypertension using quantitative magnetic resonance imaging. ( 27663418 )
2016
46
Effects of Nuclear Factor-E2-related factor 2/Heme Oxygenase 1 on splanchnic hemodynamics in experimental cirrhosis with portal hypertension. ( 28025064 )
2016
47
Use of Wireless Capsule Endoscopy for the Diagnosis and Grading of Esophageal Varices in Patients With Portal Hypertension: A Systematic Review and Meta-Analysis. ( 27548729 )
2016
48
Erratum to: Liver and spleen transient elastography predicts portal hypertension in patients with chronic liver disease: a prospective cohort study. ( 27153941 )
2016
49
Laparoscopic azygoportal disconnection with and without splenectomy for portal hypertension. ( 27568650 )
2016
50
Inflammatory Myofibroblastic Tumor of Liver Masquerading as Focal Nodular Hyperplasia in a Patient with Non-Cirrhotic Portal Hypertension and Biliary Pancreatitis. ( 27065695 )
2016

Variations for Portal Hypertension

Expression for Portal Hypertension

Search GEO for disease gene expression data for Portal Hypertension.

Pathways for Portal Hypertension

Pathways related to Portal Hypertension according to GeneCards Suite gene sharing:

(show all 24)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14 AGTR1 BMPR2 EDN1 EDNRA F2 JAK2
2
Show member pathways
13.4 AGTR1 F2 JAK2 TGFB1 THPO TNF
3
Show member pathways
13.29 BMPR2 JAK2 NOS3 TGFB1 THPO TNF
4
Show member pathways
13.19 BMPR2 EDN1 EDNRA F2 JAK2 NOS3
5
Show member pathways
12.94 ALB F2 JAK2 NOS3 TGFB1 THPO
6
Show member pathways
12.9 AGTR1 F2 JAK2 TGFB1 THPO UTS2
7
Show member pathways
12.69 AGTR1 EDN1 F2 JAK2 NOS3 TNF
8
Show member pathways
12.41 AGTR1 F2 JAK2 NOS3 TNF
9 11.86 ALB TGFB1 THPO VEGFA
10 11.79 EDN1 NOS3 VEGFA
11
Show member pathways
11.78 F2 THPO VWF
12 11.72 TGFB1 TNF VEGFA
13 11.7 NOS3 TGFB1 VWF
14 11.68 BMPR2 TGFB1 TNF
15 11.68 JAK2 TGFB1 TNF VEGFA
16
Show member pathways
11.65 AGTR1 NOS3 TGFB1
17 11.51 EDN1 TGFB1 TNF
18 11.5 BMPR2 EDN1 NOS3 TNF VEGFA
19 11.43 EDN1 NOS3 VEGFA
20 11.41 EDN1 EDNRA JAK2
21 11.16 AGTR1 EDN1 JAK2 NOS3 TGFB1 TNF
22 11.11 EDN1 EDNRA NOS3
23
Show member pathways
11.02 EDN1 JAK2 VEGFA
24 10.75 TGFB1 TNF

GO Terms for Portal Hypertension

Cellular components related to Portal Hypertension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 ALB EDN1 F2 SST TGFB1 THPO
2 caveola GO:0005901 9.5 BMPR2 JAK2 NOS3
3 extracellular space GO:0005615 9.36 ALB BMPR2 EDN1 F2 GPT SST
4 Weibel-Palade body GO:0033093 9.26 EDN1 VWF
5 platelet alpha granule lumen GO:0031093 9.26 ALB TGFB1 VEGFA VWF

Biological processes related to Portal Hypertension according to GeneCards Suite gene sharing:

(show all 31)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.93 EDN1 F2 JAK2 PKHD1 TGFB1 VEGFA
2 in utero embryonic development GO:0001701 9.9 EDN1 EDNRA NOS3 VEGFA
3 positive regulation of cell migration GO:0030335 9.88 EDN1 JAK2 TGFB1 VEGFA
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.82 JAK2 TGFB1 VEGFA
5 positive regulation of protein kinase B signaling GO:0051897 9.81 TGFB1 THPO TNF
6 platelet degranulation GO:0002576 9.81 ALB TGFB1 VEGFA VWF
7 response to wounding GO:0009611 9.8 F2 TGFB1 VWF
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.8 TGFB1 TNF VEGFA
9 regulation of cell proliferation GO:0042127 9.77 AGTR1 BMPR2 JAK2 TGFB1 TNF
10 positive regulation of endothelial cell migration GO:0010595 9.74 BMPR2 EDN1 VEGFA
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.73 EDN1 JAK2 TNF
12 extrinsic apoptotic signaling pathway GO:0097191 9.72 JAK2 TGFB1 TNF
13 lipopolysaccharide-mediated signaling pathway GO:0031663 9.67 NOS3 TGFB1 TNF
14 negative regulation of cell-cell adhesion GO:0022408 9.65 JAK2 TGFB1
15 regulation of vasodilation GO:0042312 9.65 AGTR1 UTS2
16 branching involved in blood vessel morphogenesis GO:0001569 9.65 EDN1 EDNRA VEGFA
17 response to hypoxia GO:0001666 9.65 EDN1 EDNRA TGFB1 UTS2 VEGFA
18 positive regulation of fibroblast migration GO:0010763 9.64 TGFB1 UTS2
19 artery smooth muscle contraction GO:0014824 9.62 EDN1 EDNRA
20 regulation of blood pressure GO:0008217 9.62 EDN1 EDNRA NOS3 UTS2
21 negative regulation of platelet activation GO:0010544 9.61 F2 NOS3
22 endothelial cell apoptotic process GO:0072577 9.61 BMPR2 TNF
23 positive regulation of collagen biosynthetic process GO:0032967 9.61 F2 TGFB1 UTS2
24 positive regulation of axon extension involved in axon guidance GO:0048842 9.59 BMPR2 VEGFA
25 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.58 EDN1 NOS3
26 positive regulation of protein complex assembly GO:0031334 9.58 TGFB1 TNF VEGFA
27 positive regulation of odontogenesis GO:0042482 9.54 EDN1 TGFB1
28 positive regulation of mononuclear cell migration GO:0071677 9.52 TGFB1 TNF
29 positive regulation of MAP kinase activity GO:0043406 9.46 EDN1 TGFB1 TNF VEGFA
30 positive regulation of protein phosphorylation GO:0001934 9.35 F2 TGFB1 THPO TNF VEGFA
31 positive regulation of cytosolic calcium ion concentration GO:0007204 9.02 AGTR1 EDN1 EDNRA JAK2 UTS2

Molecular functions related to Portal Hypertension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 F2 TGFB1 THPO VEGFA
2 hormone activity GO:0005179 9.26 EDN1 SST THPO UTS2
3 cytokine activity GO:0005125 9.02 EDN1 TGFB1 THPO TNF VEGFA

Sources for Portal Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....